Mustafa Memon, MD

PGY-3 @ROCRegional | @Dow_Uni 2022 | #MedTwitter

[Mustafa Memon, MD @Mustafa_memon2]

@SalmanZahidMD I loved the way you shared Dr. Anderson's incredible story. Thank you for the great presentation and warm welcome!

[Mustafa Memon, MD @Mustafa_memon2]

@RGHIMProgram Thank you for the warm welcome! 🙏🏻 I had a great time meeting everyone. Can’t wait to officially start soon! 😃

[Mustafa Memon, MD @Mustafa_memon2]

@m_naeem_88 @RGHIMProgram Thank you Dr Naeem!

[Mustafa Memon, MD @Mustafa_memon2]

Excited to share that I matched at Rochester General Hospital for Internal Medicine Residency! Can't wait to see where this next chapter of my life takes me

#Match2023 #InternalMedicine #MedTwitter @RGHIMProgram

[Mustafa Memon, MD @Mustafa_memon2]

@AnasHashem6 @RGHIMProgram Thank you so much! Excited to meet you as well!! :)

[Mustafa Memon, MD @Mustafa_memon2]

@SayedMu15532394 @RGHIMProgram Thank you Mustafa!

[Mustafa Memon, MD @Mustafa_memon2]

@BryanTanMD @RGHIMProgram Thank you so much! Would love to connect with you :)

[Mustafa Memon, MD @Mustafa_memon2]

@hurarira @RGHIMProgram Thank you Dr Hurairah!

[Aymen Ahmed @AymenAhmed_]

Out in @JACCJournals today!

Truly humbled to have our poster presented virtually at #ACC.23/WCC! We evaluated clinical, echocardiographic and safety outcomes of ARNIs in patients with STEMI. Special thanks to @IzzaShahid_ and @Mustafa_memon2 for their valuable insights.

[Mustafa Memon, MD @Mustafa_memon2]

Goodbye USMLE, you will not be missed 🥳🙏

@StoriesImg @ImgJourney @IMG_Advocate #Match2023

[Mustafa Memon, MD @Mustafa_memon2]

Congratulations Dr. @khosafaisal. So well deserved!

[Faisal Khosa @khosafaisal]

Excellence in Equity, Diversity & Inclusion Award

[Mustafa Memon, MD @Mustafa_memon2]

@JudyYeeMD @SocietyAbdRad @MontefioreRAD @MontefioreNYC @EinsteinMed Congratulations Dr. Yee!

[Mustafa Memon, MD @Mustafa_memon2]

So grateful to finally be ECFMG Certified 🎉

#Match2023 Here I come!

[Arooba Ejaz @aroobae30]

In #EJPC, our meta-analysis suggests:
🫀Baseline MRA therapy does not significantly modify efficacy of SGLT2is on clinical outcomes in HF patients
🫀15%⬇️in risk of CV death in MRA users indicates potential mortality benefit with concomitant usage of MRAs and SGLT2i
@ESC_Journals

[Aymen Ahmed @AymenAhmed_]

Out in #EJPC, we show that baseline MRA usage does not significantly modify the efficacy of SGLT2is on clinical outcomes in HF patients. However, a marked 15%⬇️in CV death risk in MRA users vs non-users suggests a potential mortality benefit with concomitant MRA and SGLT2i usage.

[Muhammad Sameer Arshad @SameerArshadMD]

#Online today in EJPC, we report the effect of MRA usage on the efficacy of SGLT2i among patients with HF.

Special thanks to @Mustafa_memon2 and @IzzaShahid_ for their guidance!

@ESC_Journals

https://t.co/XZWM86Cge7

[Mustafa Memon, MD @Mustafa_memon2]

@RamiDoukky Thank you so much Dr Doukky!

[Mustafa Memon, MD @Mustafa_memon2]

Grateful for the mentorship @ShahzebKhanMD @RamiDoukky @RichKrasuskiMD

https://t.co/uutyaj8cSN

[Mustafa Memon, MD @Mustafa_memon2]

Out now in CCI, we report that in patients undergoing TAVR:
🔹NOACs do not significantly differ from VKAs for all outcomes
🔹NOACs can be used without drawbacks of VKAs (eg, INR monitoring)
🔹Effect consistent across RCTs and observational studies

[Research Council of Pakistan @R_C_O_P]

We are proud to highlight the phenomenal work by RCOP mentee Mustafa Memon in the Canadian Association of Radiologists Journal, under the valuable mentorship of Dr. @khosafaisal.

Looking forward to many more publications in the future.

https://t.co/7ZvBQDKpwG